Ion Channel Targets in Pain Discovery: Lessons from TRPM2

Emerging biology highlights why functional validation matters

Chronic pain remains one of the most challenging therapeutic areas in drug discovery. Despite decades of research and numerous genetically validated targets, translating compelling preclinical biology into effective medicines has proven difficult.

One reason is that pain is not a single disease. Even patients sharing the same diagnosis may be driven by different underlying biological mechanisms. Understanding which pathways remain therapeutically relevant throughout disease progression is becoming increasingly important when evaluating novel therapeutic targets.

Recent research, conducted by Varghese et al. (2026), highlights the role of transient receptor potential melastatin 2 (TRPM2) in chronic pain, providing an interesting example of this challenge.

TRPM2: More than an immune-mediated pain target?

Historically, TRPM2 has primarily been associated with immune and inflammatory processes. The channel is expressed in both immune cells and sensory neurons, and previous studies suggested that its contribution to chronic pain was largely indirect through the promotion of inflammatory responses.

New evidence, however, suggests a more direct role.

Researchers have provided evidence that neuronal TRPM2 can function as a direct pain transducer, with effects that appear largely independently of immune-mediated effects. Both chronic arthritis-associated pain and neuropathic pain were significantly reduced

following neuronal TRPM2 deletion, while inflammatory responses remained largely unchanged.

Perhaps most notably, pharmacological inhibition of TRPM2 rapidly reversed established pain behaviors in preclinical models.

These findings suggest that TRPM2 may represent a convergence point where multiple inflammatory signals directly activate sensory neurons.

A key finding: biological relevance differs by disease

While the identification of a novel pain mechanism is noteworthy, the most compelling aspect of the study may be what it reveals about therapeutic opportunity.

In inflammatory arthritis models, TRPM2 dependence remained strong and persistent throughout disease progression. Local inhibition was able to reverse established pain even when inflammation remained present.

In neuropathic pain models, however, a different picture emerged.

TRPM2 played a significant role early after nerve injury, with both genetic deletion and pharmacological inhibition reducing pain hypersensitivity. Yet by later stages, knockout animals developed pain behaviors comparable to wild-type controls and pharmacological inhibition lost efficacy.

This suggests that the biological mechanisms maintaining pain can evolve over time.

For drug discovery teams, this raises an important question:

Is target expression sufficient, or must target biology remain relevant throughout the stages of disease where treatment will be administered?

Lessons for ion channel drug discovery

TRP channels have long attracted attention as potential therapeutic targets.

Members of the family, including TRPV1, TRPA1, TRPM8 and more recently TRPM2, have all demonstrated compelling links to sensory signaling, inflammation and nociception.

Yet the history of pain drug discovery has repeatedly shown that identifying target involvement is only the first step.

Successful programs require a deeper understanding of:

• Which cell types drive the response
• Whether the mechanism is maintained throughout disease progression
• Which patient populations are most likely to benefit
• How target modulation influences functional outcomes
• Whether pharmacological inhibition produces meaningful effects in relevant biological systems

This is where robust and thoughtful cellular pharmacology becomes essential.

Building confidence through functional pharmacology

As new ion channel targets emerge, high-quality functional characterization is critical for establishing whether compelling biology can translate into a therapeutic opportunity.

At Sygnature Discovery, our ion channel capabilities focus on generating data that provides confidence in critical discovery decisions.

Reflecting the importance of functional validation, our TRP Channel Discovery Platform

combines electrophysiology-based approaches with functional characterization to investigate agonist and antagonist activity across TRP family members. The platform includes established workflows for evaluating channel function and pharmacological modulation.

The platform utilizes electrophysiological methods that monitor ion channel activity through defined voltage ramp protocols, enabling quantitative assessment of channel modulation.

Importantly, assay generation alone is insufficient. The objective is to understand whether a target demonstrates the biological relevance, pharmacological tractability and translational potential necessary to support progression into discovery programs.

Looking ahead

The emergence of TRPM2 as a potential pain target highlights the challenges and opportunities associated with ion channel drug discovery. While novel biology continues to reveal promising therapeutic targets, identifying a disease-relevant mechanism is only the first step. The critical question is whether biology can be robustly translated into a tractable drug discovery program.

For ion channel targets, this requires a comprehensive understanding of target function, pharmacological modulation and the relationship between target engagement and biological outcome. Functional pharmacology plays a central role in generating the evidence needed to determine whether an emerging target warrants further investment.

At Sygnature Discovery, our ion channel expertise supports these critical decisions through electrophysiology, assay development and pharmacological characterization across challenging target classes, including members of the TRP channel family. Our TRP Channel Discovery Platform enables the generation of high-quality functional data that helps characterize channel activity, assess compound effects and build confidence in target tractability.

Whether evaluating established ion channels or newly emerging targets, Sygnature Discovery leverages over 20 years of expertise in ion channel pharmacology, electrophysiology and assay development, to generate the evidence needed to answer those questions and progress programs with confidence.

References:

• Varghese, L. Alizada, M. Yang, J. Feng, Y. Yuan, X. Malhotra, M. Zhang, X. (2026) TRPM2 is a direct pain transducer. PNAS. Available here.